CMS’ GLP-1 Bridge Demonstration—Questions and Potential Consequences
Abstract
This Viewpoint discusses the US Centers for Medicare & Medicaid Services’ (CMS) extension of the Medicare Glucagon-Like Peptide-1 (GLP-1) Bridge and outlines unanswered questions related to how the bridge will affect Medicare.
Fields of Study & Subjects
Diabetes Treatment and Management
Hyperglycemia and glycemic control in critically ill and hospitalized patients
Medication Adherence and Compliance
Publication details
- Journal / source
- JAMA
- Publisher
- American Medical Association (AMA)
- Volume
- 336
- Issue
- 4
- Pages
- 283–283
- Publication date
- 24 June 2026
- Language
- EN